Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands

Clinical Drug Investigation

Volumn 25, Issue 12, 2005, Pages 785-802

  Liedgens, Hiltrud ^a   Nuijten, Mark J C ^b   Nautrup, Barbara Poulsen ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CODEINE; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR; RANITIDINE; TRAMADOL;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DATA ANALYSIS; DECISION MAKING; DRUG COST; GASTROINTESTINAL TOXICITY; HEALTH CARE SYSTEM; HUMAN; NAUSEA; NEPHROTOXICITY; NETHERLANDS; OCCULT BLOOD; OSTEOARTHRITIS; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; VERTIGO; VOMITING;

EID: 28444452939     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525120-00005     Document Type: Article

References (68)

1. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350 (9076): 503-8
2. Srikanth VK, Fryer JL, Zhai G, et al. A meta-analysis of sex differences, prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 2005 Sep; 13 (9): 769-81
3. March LM, Bagga H. Epidemiology of osteoarthritis in Australia. Med J Aust 2004; 180 (5 Suppl.): S6-10
4. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41 (5): 778-99
5. Woo J, Lau E, Lee P, et al. Impact of osteoarthritis on quality of life in a Hong Kong Chinese population. J Rheumatol 2004; 31 (12): 2433-8
6. Groessl EJ, Kaplan RM, Cronan TA. Quality of well-being in older people with osteoarthritis. Arthritis Rheum 2003; 49 (1): 23-8
7. Jakobsson U, Hallberg IR. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs 2002; 11 (4): 430-43
8. D'Ambrosia RD. Epidemiology of osteoarthritis. Orthopedics 2005. 28 (2 Suppl): s201-5
9. Dominick KL, Ahern FM, Gold CH, et al. Health-related quality of life and health service use among older adults with osteoarthritis. Arthritis Rheum 2004; 51 (3): 326-31
10. Gabriel SE, et al. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24 (1): 43-8
11. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum 1995; 38 (10): 1351-62
12. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340 (24): 1888-99
13. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91 (3): 213-22
14. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27 (7): 1668-73
15. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18-24
16. Altman R. International experiences with diclofenac in osteoarthritis. Am J Med 1986; 80 (4B): 48-52
17. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329 (7478): 1317
18. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998. 338 (11): 727-34
19. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156 (14): 1530-6
20. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastro- duodenal damage: is prevention needed? A review and metaanalysis. J Clin Gastroenterol 1993; 17 (3): 238-43
21. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241-9
22. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162 (2): 169-75
23. Lai KC, Lam SK, Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users: a randomized trial. Aliment Pharmacol Ther 2003; 18 (8): 829-36
24. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338 (11): 719-26
25. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106 (5B): 13S-24S
26. Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995; 88 (8): 551-7
27. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44 (3): 215-32
28. Zazioco G. COX-2 inhibitors: the battle for market dominance. Drug Market Dev 2001; 12 (5): 131-7
29. Champion GD, Feng PH, Azuma T, et al. NSAID-induced gastrointestinal damage: epidemiology, risk and prevention, with an evaluation of the role of misoprostol: an Asia-Pacific perspective and consensus. Drugs 1997; 53 (1): 6-19
30. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001; 19 (6): 655-65
31. Chevat C, Pena BM, Al MJ, et al. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 2001; 19 Suppl. 1: 17-32
32. FitzGerald GA, Patrono C. The COXIBs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345 (6): 433-42
33. Noble SL, King DS, Olutade JI. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician 2000; 61 (12): 3669-76
34. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343 (21): 1520-8
35. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284 (10): 1247-55
36. Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25 (7): 537-44
37. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7 (3): 159-75
38. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352 (11): 1092-102
39. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352 (11): 1071-80
40. Chancellor JV, Hunsche E, de Cruz E, et al. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19 Suppl. 1: 59-75
41. Kamath CC, Kremers HM, Vanness DJ, et al. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003; 6 (2): 144-57
42. Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care 2003; 9 (12): 785-94
43. McClellan K, Scott LJ. Tramadol/paracetamol. Drugs 2003; 63 (11): 1079-86
44. Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 2001; 26 (4): 257-64
45. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet 2004; 43 (13): 879-923
46. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44 (7): 1587-98
47. Case, JP, Baliunas AJ, et al. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003; 163 (2): 169-78
48. Adler L, McDonald C, O'Brien C, et al. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol 2002; 29 (10): 2196-9
49. Rosenthal NR, Silverfield JC, Wu SC, et al. Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc 2004; 52 (3): 374-80
50. Edwards JE, McQuay HJ, Moore RA. Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain. J Pain Symptom Manage 2002; 23 (2): 121-30
51. Pavelka K, Peliskova Z, Stehlikova H. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac and tramadol. Clin Drug Invest 1998; 16 (6): 421-9
52. Alwine LK. TRAMAP-ANA-006 Study Group. Long-term (2 years) analgesic efficacy of tramadol/acetaminophen tablets [abstract]. Annual European Congress of Rheumatology, EULAR; 2000 Jun 21-24; Nice
53. Burke TA, Zabinski RA, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001; 19 Suppl. 1: 33-47
54. Pharmakotherapeutisch Kompas. Netherlands, 2005 [online]. Available from URL: http://www.cvzkompassen.nl/fk/ [Accessed 2005 May]
55. Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001; 23 (9): 1429-45
56. Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19 Suppl. 1: 49-58
57. Peloso P, Rosenthal N, Wu S, et al. A pooled analysis of tramadol/acetaminophen tablets for treatment of lower back pain in an elderly patient population. Am Ger Soc 2003; 51 Suppl. 4: S143-4
58. Central Tariffs for consultations and procedures in health care. Utrecht: College Tarieven Gezondheidszorg, 2003
59. Oostenbrink J, Koopmanschap M, Rutten FF. Handleiding voor kostenonderzoek. CVZ 2001, 70-103
60. Axon Pharius Data 2005 [online]. Available from URL: http://www.zindex.nl [Accessed 2005 May]
61. Stichting Renine, Registratie Nierfunktievervanging Nederland [online]. Available from URL: http://www.renine.nl [Accessed 2005 May]
62. de Leest H, van Dieten H, van Tulder M, et al. Costs of treating bleeding and perforated peptic ulcers in The Netherlands. J Rheumatol 2004; 31 (4): 788-91
63. Nuijten M, Poulsen Nautrup B. Cost effectiveness of the combination tramadol plus paracetamol in treatment of subacute low back pain in a Dutch health care setting [abstract]. Value Health 2004; 7 (6): 724
64. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343 (8905): 1075-8
65. Schaefer M, DeLattre M, Gao X, et al. Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr Med Res Opin 2005; 21 (1): 47-60
66. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330 (7504): 1366
67. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165 (9): 978-84
68. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365 (9458): 475-81